NCT03059641 is a clinical trial in Lung Neoplasms, sponsored by Geneplus-Beijing Co. Ltd..

Who is sponsoring NCT03059641?

NCT03059641 is sponsored by Geneplus-Beijing Co. Ltd..

What condition does NCT03059641 study?

NCT03059641 studies Lung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung, Squamous Cell Lung Cancer.

Is NCT03059641 still recruiting?

NCT03059641 is currently completed. Last updated 5 February 2020.

Last reviewed 2020-02-05 · How we verify

NCT03059641

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

Completed Last updated 5 February 2020

What this trial tests

trial in Lung Neoplasms in 300 participants. Completed in 30 January 2020.

Timeline

22 February 2017

Primary endpoint
31 December 2019

30 January 2020

Quick facts

Lead sponsor	Geneplus-Beijing Co. Ltd.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	300
Start date	22 February 2017
Primary completion	31 December 2019
Estimated completion	30 January 2020
Sites	14 locations across China

Conditions studied

Lung Neoplasms — all drugs for Lung Neoplasms →
Lung Cancer, Nonsmall Cell — all drugs for Lung Cancer, Nonsmall Cell →
Adenocarcinoma of Lung — all drugs for Adenocarcinoma of Lung →
Squamous Cell Lung Cancer — all drugs for Squamous Cell Lung Cancer →

Sponsor

Geneplus-Beijing Co. Ltd.

Who can join

Adults 18 to 80, any sex, with Lung Neoplasms or Lung Cancer, Nonsmall Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the concordance of sensitizing mutations detected between paired plasma and tissue samples; the correlation between the clonal status of sensitizing mutations and targeted therapy response; and the prognostic impact of the relative abundance of sensitizing / resistance mutations.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Cell-free DNA analysis in current cancer clinical trials: a review.
Cisneros-Villanueva M, Hidalgo-Pérez L, Rios-Romero M, Cedro-Tanda A, et al · · 2022 · cited 137× · PMID 35027672 · DOI 10.1038/s41416-021-01696-0
Clonal Architecture of <i>EGFR</i> Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641).
Ai X, Cui J, Zhang J, Chen R, et al · · 2021 · cited 41× · PMID 33188140 · DOI 10.1158/1078-0432.ccr-20-3063
Liquid Biopsies: Emerging role and clinical applications in solid tumours.
Sisodiya S, Kasherwal V, Khan A, Roy B, et al · · 2023 · cited 21× · PMID 37327582 · DOI 10.1016/j.tranon.2023.101716
Plasma-Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: A Health Technology Assessment.
Ontario Health (Quality) . · · 2024 · PMID 39698418
SAFE-MIL: a statistically interpretable framework for screening potential targeted therapy patients based on risk estimation.
Guan Y, Xue Z, Wang J, Ai X, et al · · 2024 · PMID 39211737 · DOI 10.3389/fgene.2024.1381851

Verify or expand the search:

Other recruiting trials for Lung Neoplasms

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07109154 — DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First- · recruiting
NCT06974604 — Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM · Phase 2 · recruiting
NCT07165691 — TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics · NA · recruiting

Other Geneplus-Beijing Co. Ltd. trials

Trials by the same sponsor.

NCT06876610 — Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer · recruiting
NCT06283875 — The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer · not yet recruiting
NCT05415670 — Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(GM-seq) · completed
NCT05292443 — Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer · withdrawn
NCT04566432 — Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03059641 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Geneplus-Beijing Co. Ltd.
Last refreshed: 5 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03059641.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing